• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Proposal for harmonizing the reporting of infections during treatment with bispecific antibodies in multiple myeloma.

作者信息

Ludwig Heinz, Munshi Nikhil C, Terpos Evangelos, Schweitzer Ilvy, Raje Noopur, Moreau Philippe, Nooka Ajay

机构信息

Department of Medicine I, Wilhelminen Cancer Research Institute, Clinic Ottakring, Vienna, Austria.

Dana-Farber Cancer Institute, Department of Medicine and Boston VA Healthcare System, Boston, MA.

出版信息

Blood Adv. 2024 Sep 24;8(18):4979-4982. doi: 10.1182/bloodadvances.2024013461.

DOI:10.1182/bloodadvances.2024013461
PMID:38776433
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11496977/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7391/11496977/a2f413ff779f/BLOODA_ADV-2024-013461-gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7391/11496977/a2f413ff779f/BLOODA_ADV-2024-013461-gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7391/11496977/a2f413ff779f/BLOODA_ADV-2024-013461-gr1.jpg

相似文献

1
Proposal for harmonizing the reporting of infections during treatment with bispecific antibodies in multiple myeloma.关于统一多发性骨髓瘤双特异性抗体治疗期间感染报告的提案。
Blood Adv. 2024 Sep 24;8(18):4979-4982. doi: 10.1182/bloodadvances.2024013461.
2
Mitigating infection risks: The promise and challenge of bispecific antibodies in haematological malignancies.减轻感染风险：双特异性抗体在血液恶性肿瘤中的前景与挑战。
Br J Haematol. 2024 Sep;205(3):764-766. doi: 10.1111/bjh.19668. Epub 2024 Jul 22.
3
Defining infection risk of bispecific antibodies for myeloma.确定双特异性抗体治疗骨髓瘤的感染风险
Blood Adv. 2024 Sep 24;8(18):4977-4978. doi: 10.1182/bloodadvances.2024013813.
4
Management of Toxicities Associated with BCMA, GPRC5D, and FcRH5-Targeting Bispecific Antibodies in Multiple Myeloma.多发性骨髓瘤中针对 BCMA、GPRC5D 和 FcRH5 的双特异性抗体相关毒性的管理。
Curr Hematol Malig Rep. 2024 Dec;19(6):237-245. doi: 10.1007/s11899-024-00740-z. Epub 2024 Aug 15.
5
Sustained remission following finite duration bispecific antibody therapy in patients with relapsed/refractory myeloma.复发/难治性骨髓瘤患者接受有限疗程双特异性抗体治疗后的持续缓解
Blood Cancer J. 2024 Aug 12;14(1):137. doi: 10.1038/s41408-024-01114-7.
6
Immune prognostic score predicts the risk of infection and survival outcomes in patients with relapsed multiple myeloma treated with bispecific antibodies.免疫预后评分预测了接受双特异性抗体治疗的复发性多发性骨髓瘤患者感染风险和生存结局。
Br J Haematol. 2024 Nov;205(5):1830-1834. doi: 10.1111/bjh.19700. Epub 2024 Aug 27.
7
[Bispecific antibodies in multiple myeloma].[多发性骨髓瘤中的双特异性抗体]
Bull Cancer. 2021 Oct;108(10S):S205-S212. doi: 10.1016/j.bulcan.2021.10.003.
8
Characteristics and incidence of infections in patients with multiple myeloma treated by bispecific antibodies: a national retrospective study.双特异性抗体治疗多发性骨髓瘤患者的感染特征和发生率：一项全国性回顾性研究。
Clin Microbiol Infect. 2024 Jun;30(6):764-771. doi: 10.1016/j.cmi.2024.02.023. Epub 2024 Mar 1.
9
BiTEing the Tumor.靶向肿瘤
J Clin Oncol. 2020 Jun 20;38(18):2077-2079. doi: 10.1200/JCO.20.00223. Epub 2020 May 6.
10
Bispecific antibodies in the treatment of multiple myeloma.双特异性抗体在多发性骨髓瘤治疗中的应用。
Blood Cancer J. 2024 Sep 12;14(1):158. doi: 10.1038/s41408-024-01139-y.

引用本文的文献

1
T-Cell Redirecting Therapies in Multiple Myeloma: Pathogenesis and Management of Toxicities Beyond CRS and ICANS.多发性骨髓瘤中的T细胞重定向疗法：细胞因子释放综合征和免疫效应细胞相关神经毒性综合征之外的发病机制及毒性管理
Cancers (Basel). 2025 Apr 30;17(9):1514. doi: 10.3390/cancers17091514.
2
Teclistamab in relapsed refractory multiple myeloma: a multi-institutional real-world study from the French early access program.替西妥单抗治疗复发难治性多发性骨髓瘤：一项来自法国早期准入项目的多机构真实世界研究。
Haematologica. 2025 Apr 1;110(4):990-994. doi: 10.3324/haematol.2024.286118. Epub 2024 Nov 21.
3
Defining infection risk of bispecific antibodies for myeloma.

本文引用的文献

1
Predictors of early morbidity and mortality in newly diagnosed multiple myeloma: data from five randomized, controlled, phase III trials in 3700 patients.新诊断多发性骨髓瘤患者早期发病率和死亡率的预测因素：来自 3700 例患者的五项随机对照 III 期临床试验数据。
Leukemia. 2024 Mar;38(3):640-647. doi: 10.1038/s41375-023-02105-6. Epub 2023 Dec 7.
2
Teclistamab impairs humoral immunity in patients with heavily pretreated myeloma: importance of immunoglobulin supplementation.特卡昔单抗可损害经大量预处理的骨髓瘤患者的体液免疫：免疫球蛋白补充的重要性。
Blood Adv. 2024 Jan 9;8(1):194-206. doi: 10.1182/bloodadvances.2023011658.
3
Incidence, timing, and management of infections in patients receiving teclistamab for the treatment of relapsed/refractory multiple myeloma in the MajesTEC-1 study.
确定双特异性抗体治疗骨髓瘤的感染风险
Blood Adv. 2024 Sep 24;8(18):4977-4978. doi: 10.1182/bloodadvances.2024013813.
4
Improving infection reporting in hematology treatment trials.改善血液学治疗试验中的感染报告。
Blood Adv. 2024 Nov 26;8(22):5925-5926. doi: 10.1182/bloodadvances.2024013859.
在MajesTEC-1研究中接受替西妥单抗治疗复发/难治性多发性骨髓瘤患者的感染发生率、发生时间及管理
Cancer. 2024 Mar 15;130(6):886-900. doi: 10.1002/cncr.35107. Epub 2023 Nov 14.
4
Elranatamab in relapsed or refractory multiple myeloma: the MagnetisMM-1 phase 1 trial.埃尔拉纳他单抗治疗复发/难治性多发性骨髓瘤：MagnetisMM-1 期临床试验。
Nat Med. 2023 Oct;29(10):2570-2576. doi: 10.1038/s41591-023-02589-w. Epub 2023 Oct 2.
5
The changing spectrum of infection with BCMA and GPRC5D targeting bispecific antibody (bsAb) therapy in patients with relapsed refractory multiple myeloma.复发/难治性多发性骨髓瘤患者中，针对 BCMA 和 GPRC5D 的双特异性抗体（bsAb）治疗的感染谱变化。
Haematologica. 2024 Mar 1;109(3):906-914. doi: 10.3324/haematol.2023.283590.
6
Increased risk of infection reporting with anti-BCMA bispecific monoclonal antibodies in multiple myeloma: A worldwide pharmacovigilance study.多发性骨髓瘤中抗B细胞成熟抗原双特异性单克隆抗体感染报告风险增加：一项全球药物警戒研究。
Am J Hematol. 2023 Dec;98(12):E349-E353. doi: 10.1002/ajh.27071. Epub 2023 Aug 30.
7
Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results.Elranatamab 治疗复发/难治性多发性骨髓瘤：MagnetisMM-3 期临床试验结果。
Nat Med. 2023 Sep;29(9):2259-2267. doi: 10.1038/s41591-023-02528-9. Epub 2023 Aug 15.
8
Respiratory infections predominate after day 100 following B-cell maturation antigen-directed CAR T-cell therapy.在 B 细胞成熟抗原导向的 CAR T 细胞治疗后 100 天后，呼吸道感染占主导地位。
Blood Adv. 2023 Sep 26;7(18):5485-5495. doi: 10.1182/bloodadvances.2023010524.
9
Infection rates are high across the multiple myeloma continuum, not just with bispecific antibodies.在多发性骨髓瘤的整个病程中感染率都很高，不仅仅是使用双特异性抗体时如此。
Eur J Cancer. 2023 Aug;189:112926. doi: 10.1016/j.ejca.2023.05.014. Epub 2023 Jun 10.
10
CONSORT Harms 2022 statement, explanation, and elaboration: updated guideline for the reporting of harms in randomised trials.CONSORT危害声明2022：解释与阐述——随机对照试验中危害报告的更新指南
BMJ. 2023 Apr 24;381:e073725. doi: 10.1136/bmj-2022-073725.